Novo announced (press release) the acquisition of Ziylo, a small incubator company based out of the University of Bristol developing synthetic glucose binding molecules. The purchase of Ziylo aligns with Novo’s strategic goal of developing glucose responsive insulin.
Xeris, Tandem, and Voluntis have announced news related to their respective diabetes business units. Below, FENIX has provided a summary of these updates, the most interesting of which is from Xeris.
Novo Nordisk’s Tresiba PI was updated in the Drugs@FDA database on August 14, 2018, to reflect changes in the safety outcomes related to immunogenicity.
Zealand hosted its Q2 ’18 earnings call (press release) and provided updates on its diabetes portfolio including dasiglucagon, which is being studied for three distinct indications (hypoglycemia rescue, use in a dual-hormone pump, and congenital hyperinsulinism).
Xeris Pharmaceuticals filed its first 10-Q statement since its IPO in June 2018. In the 10-Q, Xeris confirmed filing of its Glucagon Rescue Pen in Q3 ‘18 via the 505(b)(2) pathway. Yesterday, Xeris released its Q2 ’18 earnings but did not have an associated earnings webcast.
Xeris Pharmaceuticals released its Q2 ’18 earnings and disclosed the NDA submission for its Glucagon Rescue Pen. While Xeris did not specify the filing date, it is assumed to have occurred in July or August in accordance with timing from the company’s S-1 document.
Medtronic announced the launch of its “Inner Circle” patient engagement program for patients on either the 670G hybrid closed-loop or the standalone Guardian Connect CGM. Recall, Medtronic initially disclosed its plans for Inner Circle during the June 2018 Investor Day.
ADA has issued an updated position statement on the treatment of pediatric patients with T1DM.
Novo Nordisk hosted its post-Q2 ’18 earnings event in London. The format of the event was different than in past quarters. This event started with a short presentation by Novo’s CEO and was followed by a “Meet the Management” session that was not available through webcast. Below are highlights from the available presentation.
Senseonics hosted its Q2 ’18 earnings call and provided insight into their raised financial guidance, the recent Eversense implantable CGM US launch, and LCM activities. Below, FENIX provides highlights from the call, in addition to insight on a potential Senseonics acquisition strategy targeted at Roche Diabetes Care.